Literature DB >> 16123217

Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Katia Perruccio1, Antonella Tosti, Emanuela Burchielli, Fabiana Topini, Loredana Ruggeri, Alessandra Carotti, Marusca Capanni, Elena Urbani, Antonella Mancusi, Franco Aversa, Massimo F Martelli, Luigina Romani, Andrea Velardi.   

Abstract

Aspergillus and cytomegalovirus are major causes of morbidity/mortality after haploidentical hematopoietic transplantation. The high degree of mismatching makes cell immunotherapy impossible as it would result in lethal graft-versus-host disease (GvHD). We generated large numbers of donor T-cell clones specific for Aspergillus or cytomegalovirus antigens. We identified clones potentially responsible for causing GvHD by screening them for cross-reactivity against recipient mononuclear cells. Non-recipient reactive, pathogen-specific clones were infused soon after transplantation. They were CD4+ and produced high levels of interferon-gamma and low levels of interleukin-10. In 46 control transplant recipients who did not receive adoptive therapy, spontaneous pathogen-specific T cells occurred in low frequency 9 to 12 months after transplantation and displayed a non-protective low interferon-gamma/high interleukin-10 production phenotype. In the 35 recipients who received adoptive therapy, one single infusion of donor alloantigen-deleted, pathogen-specific clones in the dose range of 10(5) to 10(6) cells/kg body weight did not cause GvHD and induced high-frequency T-cell responses to pathogens, which exhibited a protective high interferon-gamma/low interleukin-10 production phenotype within 3 weeks of infusion. Frequencies of pathogen-specific T cells remained stable over time, and were associated with control of Aspergillus and cytomegalovirus antigenemia and infectious mortality. This study opens new perspectives for reducing infectious mortality after haploidentical transplantations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123217      PMCID: PMC1895249          DOI: 10.1182/blood-2005-05-1775

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

2.  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.

Authors:  Laila E Gamadia; Ester B M Remmerswaal; Jan F Weel; Frederieke Bemelman; René A W van Lier; Ineke J M Ten Berge
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

3.  Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease.

Authors:  François Boutboul; Corinne Alberti; Thierry Leblanc; Annie Sulahian; Eliane Gluckman; Francis Derouin; Patricia Ribaud
Journal:  Clin Infect Dis       Date:  2002-02-20       Impact factor: 9.079

4.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

5.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study.

Authors:  Isabelle André-Schmutz; Françoise Le Deist; Salima Hacein-Bey-Abina; Ellen Vitetta; John Schindler; Gaelle Chedeville; Etienne Vilmer; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

7.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

8.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

Authors:  Kieren A Marr; Rachel A Carter; Michael Boeckh; Paul Martin; Lawrence Corey
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

9.  Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies.

Authors:  Holger Hebart; Claudia Bollinger; Paul Fisch; Jacqueline Sarfati; Christoph Meisner; Manuela Baur; Jürgen Loeffler; Michel Monod; Jean-Paul Latgé; Hermann Einsele
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.

Authors:  Evren Ozdemir; Lisa S St John; Geraldine Gillespie; Sarah Rowland-Jones; Richard E Champlin; Jeffrey J Molldrem; Krishna V Komanduri
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

View more
  105 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 3.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

Review 4.  Aspergillus fumigatus: principles of pathogenesis and host defense.

Authors:  Tobias M Hohl; Marta Feldmesser
Journal:  Eukaryot Cell       Date:  2007-09-21

5.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 6.  Aspergillus vaccines: Hardly worth studying or worthy of hard study?

Authors:  Stuart M Levitz
Journal:  Med Mycol       Date:  2016-09-17       Impact factor: 4.076

7.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 8.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

9.  Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications.

Authors:  M Di Ianni; B Del Papa; D Cecchini; E Bonifacio; L Moretti; T Zei; R Iacucci Ostini; F Falzetti; L Fontana; G Tagliapietra; C Maldini; M F Martelli; A Tabilio
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

10.  Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Authors:  Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.